# US 9,750,688 B2 · Glucan gels > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,750,688 B2 - Document ID: US9750688B2 - Status: Granted - Kind: B2 - Application number: 15/066,748 - Filed: 2016-03-10 - Published: 2016-09-08 - Granted: 2017-09-05 - Earliest claimed: 2010-11-29 - Assignees: Biotec Pharmacon ASA - Applicants: Biotec Pharmacon Asa - Inventors: Rolf Engstad; Stein-Tore Solem; Dag-Eirik Ramsøy - Web page: https://patentgrep.com/patent/US9750688B2 ## CPC - A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 31/716: Glucans - A61L 15/00: Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads (for liquid bandages A61L26/00; radioactive dressings {A61N5/1029}) - A61L 26/0023: {Polysaccharides} - A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis - A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like - A61P 35/00: Antineoplastic agents - C08B 37/0024: {beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof} - C08J 3/075: Macromolecular gels - C08J 2305/00: Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00 - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21) - C08J: WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H (working, e.g. shaping, of plastics B29) ## Abstract The present invention relates to a glucan having a weight average molar mass of 15,000 to 50,000 g/mol on a single chain basis and a weight average molar mass in aqueous solution on an aggregate basis of 4 to 20×105 g/mol and existing in gel form in aqueous solution at a concentration ≧1% at 25° C. and neutral pH and having a melting temperature (gel to sol) of 35 to 60° C. when the glucan is dissolved in water at a concentration of 2%, methods for the production thereof, medical uses thereof, physical supports having the glucan applied thereto or impregnated thereon and in vitro methods of proliferation of skin cells which comprise contacting a population of skin cells with the glucan. ## Claims ### Claim 1 A method of assisting wound or ulcer healing or treating oral mucositis or cancer in a subject in need thereof which comprises administering to said subject a gel glucan product comprising a soluble yeast glucan in aqueous solution at a concentration of 1 to 6%, the glucan having a weight average molar mass of 15,000 to 50,000 g/mol on a single chain basis and a weight average molar mass in aqueous solution on an aggregate basis of 4 to 20×105 g/mol, the gel glucan product having a gel to sol melting temperature of 35 to 60° C. ### Claim 2 (depends on 1) The method of claim 1, wherein the glucan has a weight average molar mass of 20,000 to 40,000 g/mol on a single chain basis. ### Claim 3 (depends on 1) The method of claim 1, wherein the gel glucan product has a melting temperature (gel to sol) of about 40° C. ### Claim 4 (depends on 1) The method of claim 1, wherein the glucan is in aqueous solution at a concentration of 2% to 4%. ### Claim 5 (depends on 1) The method of claim 1, wherein the glucan is in aqueous solution at a concentration of about 2%. ### Claim 6 (depends on 1) The method of claim 1, wherein the glucan is derived from Saccharomyces cerevisiae. ### Claim 7 (depends on 1) The method of claim 1, wherein the glucan is a beta glucan comprising a backbone of β-(1,3)-linked glucosyl residues and side chains comprising 2 or more β-(1,3)-linked glucosyl residues, the sidechains being attached to the backbone via a β-(1,6)-linkage. ### Claim 8 (depends on 1) The method of claim 1, wherein the glucan is essentially free of repetitive β-(1,6)-linked glucosyl residues. ### Claim 9 (depends on 1) The method of claim 1, wherein said ulcer is a diabetic ulcer. ### Claim 10 (depends on 1) The method of claim 1, wherein the glucan is topically applied to a subject. ### Claim 11 A physical support having applied thereto or impregnated therein, a gel glucan product comprising a soluble yeast glucan in aqueous solution at a concentration of 1 to 6%, the glucan having a weight average molar mass of 15,000 to 50,000 g/mol on a single chain basis and a weight average molar mass in aqueous solution on an aggregate basis of 4 to 20×105 g/mol, the gel glucan product having a gel to sol melting temperature of 35 to 60° C. ### Claim 12 (depends on 11) The physical support of claim 11 selected from the group consisting of a woven, non-woven, knitted, foam or adhesive substrate; a patch, dressing, plaster, bandage, film or gauze. ### Claim 13 An in vitro method of proliferation of skin cells which comprises contacting a population of skin cells with a gel glucan product comprising a soluble yeast glucan in aqueous solution at a concentration of 1 to 6%, the glucan having a weight average molar mass of 15,000 to 50,000 g/mol on a single chain basis and a weight average molar mass in aqueous solution on an aggregate basis of 4 to 20×105 g/mol, the gel glucan product having a gel to sol melting temperature of 35 to 60° C.